Maryland State Retirement & Pension System bought a new position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,372 shares of the biotechnology company’s stock, valued at approximately $220,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in shares of Cerevel Therapeutics by 1.6% in the 4th quarter. Principal Financial Group Inc. now owns 27,117 shares of the biotechnology company’s stock worth $1,150,000 after buying an additional 430 shares during the last quarter. American International Group Inc. lifted its stake in Cerevel Therapeutics by 1.6% in the first quarter. American International Group Inc. now owns 35,294 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 546 shares during the last quarter. Headlands Technologies LLC purchased a new position in Cerevel Therapeutics in the first quarter valued at approximately $26,000. Amalgamated Bank lifted its stake in Cerevel Therapeutics by 8.8% in the fourth quarter. Amalgamated Bank now owns 10,027 shares of the biotechnology company’s stock valued at $425,000 after purchasing an additional 809 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Cerevel Therapeutics by 5.1% in the fourth quarter. New York State Common Retirement Fund now owns 28,535 shares of the biotechnology company’s stock valued at $1,210,000 after purchasing an additional 1,383 shares during the last quarter. Hedge funds and other institutional investors own 87.73% of the company’s stock.
Cerevel Therapeutics Price Performance
Cerevel Therapeutics stock opened at $44.96 on Thursday. Cerevel Therapeutics Holdings, Inc. has a 12 month low of $19.59 and a 12 month high of $44.99. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60. The business’s 50 day simple moving average is $43.58 and its 200 day simple moving average is $42.35. The company has a market cap of $8.19 billion, a price-to-earnings ratio of -16.47 and a beta of 1.40.
Insider Activity at Cerevel Therapeutics
About Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Read More
- Five stocks we like better than Cerevel Therapeutics
- The How And Why of Investing in Oil Stocks
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- What is the Euro STOXX 50 Index?
- Introduction to Fibonacci Retracement Levels
- Find and Profitably Trade Stocks at 52-Week Lows
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Want to see what other hedge funds are holding CERE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report).
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.